Inspire Medical Systems (INSP) stock has significantly underperformed peers over the past year, reflecting its -0.38 12-month market return compared to some rivals' positive performance. While exhibiting solid LTM revenue growth of 16.8%, its LTM operating margin of 4.16% and FCF margin of 11.2% lag some key competitors. A high PE ratio of 77.2 suggests a rich valuation relative to profitable peers, potentially limiting upside despite robust top-line expansion.
INSP's lower 4.2% operating margin vs. GMED's 15.7% suggests less pricing power or heavier reinvestment in market development.INSP's 16.8% revenue growth, outpacing GMED but trailing MASI, indicates strong niche expansion despite broader market competition.INSP's 37.9% stock decline and 77.2 PE, while peers rose, reflects investor skepticism on future growth potential or valuation premium.
Here's how Inspire Medical Systems stacks up across size, valuation, and profitability versus key peers.
INSPGMEDPENMASINVCRMarket Cap ($ Bil)3.411.811.67.91.4Revenue ($ Bil)0.92.81.32.20.6PE Ratio77.227.971.0-13.8-7.9LTM Revenue Growth16.8%11.7%14.6%38.5%11.2%LTM Operating Margin4.2%15.7%13.0%6.1%-27.5%LTM FCF Margin11.2%20.6%11.4%7.7%-10.1%12M Market Return-37.9%3.8%21.8%-15.8%-29.3%
For more details on Inspire Medical Systems, read Buy or Sell INSP Stock. Below we compare INSP's growth, margin, and valuation with peers across years
